Abstract
Metabotropic glutamate receptor 5 (mGlu5) is a class C G-protein-coupled receptor which possesses a large extracellular N-terminal domain (ATD) connected to the seven-transmembrane (7-TM) domain. In contrast to the glutamate and its close analogs binding at the orthosteric site on the ATD region, allosteric modulators bind at topographically distinct sites in the 7-TM region. Activation of mGlu5 receptors at either the orthosteric or allosteric sites results in enhancement of NMDA receptor function and represents a promising opportunity for the treatment of schizophrenia. Since the disclosure of the first mGlu5 positive allosteric modulators (PAM) in 2003, there have been intense industry-wide efforts to discover and develop safe and efficacious agents capable of selectively enhancing mGlu5 receptor function at the allosteric sites. Over the past decade, tremendous progress has been made, and multiple chemical scaffolds have been identified as mGlu5 PAMs, possibly binding to different allosteric sites on the 7-TM domain. These ligands have helped gain novel insights into the biology of mGlu5 receptor allosteric activation. Here we provide a comprehensive review on the structure-activity relationship (SAR) progress on the mGlu5 PAMs reported in the primary literature and include appropriate and complementary examples from the patent literature. Important in vivo studies of select compounds from individual scaffolds are highlighted, and challenges facing the clinical development of mGlu5 receptor PAMs are discussed.
Keywords: GPCR, mGlu5 receptor, positive allosteric modulators (PAM), SAR, schizophrenia.
Current Topics in Medicinal Chemistry
Title:SAR Studies on mGlu5 Receptor Positive Allosteric Modulators (2003- 2013)
Volume: 14 Issue: 15
Author(s): Junliang Hao and Hui Xiong
Affiliation:
Keywords: GPCR, mGlu5 receptor, positive allosteric modulators (PAM), SAR, schizophrenia.
Abstract: Metabotropic glutamate receptor 5 (mGlu5) is a class C G-protein-coupled receptor which possesses a large extracellular N-terminal domain (ATD) connected to the seven-transmembrane (7-TM) domain. In contrast to the glutamate and its close analogs binding at the orthosteric site on the ATD region, allosteric modulators bind at topographically distinct sites in the 7-TM region. Activation of mGlu5 receptors at either the orthosteric or allosteric sites results in enhancement of NMDA receptor function and represents a promising opportunity for the treatment of schizophrenia. Since the disclosure of the first mGlu5 positive allosteric modulators (PAM) in 2003, there have been intense industry-wide efforts to discover and develop safe and efficacious agents capable of selectively enhancing mGlu5 receptor function at the allosteric sites. Over the past decade, tremendous progress has been made, and multiple chemical scaffolds have been identified as mGlu5 PAMs, possibly binding to different allosteric sites on the 7-TM domain. These ligands have helped gain novel insights into the biology of mGlu5 receptor allosteric activation. Here we provide a comprehensive review on the structure-activity relationship (SAR) progress on the mGlu5 PAMs reported in the primary literature and include appropriate and complementary examples from the patent literature. Important in vivo studies of select compounds from individual scaffolds are highlighted, and challenges facing the clinical development of mGlu5 receptor PAMs are discussed.
Export Options
About this article
Cite this article as:
Hao Junliang and Xiong Hui, SAR Studies on mGlu5 Receptor Positive Allosteric Modulators (2003- 2013), Current Topics in Medicinal Chemistry 2014; 14 (15) . https://dx.doi.org/10.2174/1568026614666140826120419
DOI https://dx.doi.org/10.2174/1568026614666140826120419 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Anticancer Peptides and Proteins: A Panoramic View
Protein & Peptide Letters Anticancer Drugs Targeting the Apoptotic Pathway
Medicinal Chemistry Reviews - Online (Discontinued) Achievements and Bottlenecks of PEGylation in Nano-delivery Systems
Current Medicinal Chemistry Triggers for Acceptance of COVID-19 Vaccination: A Community- Based Study
Recent Advances in Anti-Infective Drug Discovery Dipeptidyl Peptidase IV Inhibitors: A New Paradigm in Type 2 Diabetes Treatment
Current Drug Targets Relation between Soluble CD14 Levels, Inflammation, Subclinical Atherosclerosis and Mortality in Hemodialysis Patients
Endocrine, Metabolic & Immune Disorders - Drug Targets An Antifungal Peptide with Antiproliferative Activity Toward Tumor Cells from Red Kidney Beans
Protein & Peptide Letters Safety Profile of Oral Iron Chelator Deferiprone in Chinese Children with Transfusion-Dependent Thalassaemia
Current Drug Safety How Does the Covıd-19 Pandemıc Affect the Target 90-90-90?
Current HIV Research Immunosuppressant Drugs and Covid-19: Associated Risks, Drug-Drug Interactions and Contraindications
Coronaviruses A Review on Synthetic and Natural Steroid Dimers: 1997-2006
Current Medicinal Chemistry Anti-Cancer Drug Design Using Natural and Synthetic Pharmacophores
Current Organic Chemistry Computational Studies of Budesonide vs. Vilanterol: Asthma Drugs Against SARS-CoV-2 M<sup>pro</sup>
Current Chinese Science Synthesis of Substituted Imidazo[1,5-a]pyrimidines, 1H-pyrrolo[2,3- b]pyridines and 3-methyl-3H-imidazo[4,5-b]pyridines
Letters in Organic Chemistry 6-Membered Pyrrololactams: An Overview of Current Synthetic Approaches to their Preparation
Current Organic Chemistry Rethinking Target Discovery in Polygenic Diseases
Current Topics in Medicinal Chemistry Persistent Hiccups as an Atypical Initial Presentation of COVID-19: A Case Report
Infectious Disorders - Drug Targets Cytokine Storm and Neuropathological Alterations in Patients with Neurological Manifestations of COVID-19
Current Alzheimer Research The Comprehensive Appraisal of COVID-19: Its’ Clinical Panorama from Virology till Management and Beyond
Coronaviruses The Chemistry of 4-(dicyanomethylene)-3-methyl-l-phenyl-2-pyrazoline-5-ones as a Privileged Scaffold in the Synthesis of Heterocycles
Current Organic Synthesis